Navigation Links
Ambulatory Services of America, Inc. Announces Investment by Lindsay Goldberg
Date:5/20/2008

NASHVILLE, Tenn., May 20 /PRNewswire/ -- Ambulatory Services of America, Inc. today announced that Lindsay Goldberg has invested $75 million in Ambulatory Services of America. ASA will use the funds to close several identified acquisitions and to enable its growth strategy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071218/CLTU087LOGO )

Ambulatory Services of America was founded in 2006 to provide alternate-site health care services in partnership with physicians. In December 2007, ASA completed the acquisition of Innovative Dialysis Systems and related dialysis joint ventures, which provided care to more than 3,000 patients with end-stage renal disease through 35 dialysis programs. ASA is led by a management team with a strong record of success in health care services. Timothy Martin, President and Chief Executive Officer of ASA, was Executive Vice President and Chief Operating Officer of Renal Care Group, Inc. when Fresenius Medical Care NA acquired it for $4.0 billion in March of 2006.

Mr. Martin said, "We are extremely pleased that Lindsay Goldberg has given our management team and strategy this vote of confidence. We have a great opportunity to continue our growth in alternate-site health care services, focusing on the radiation oncology and dialysis sectors. We selected Lindsay Goldberg based on their commitment to support our disciplined growth, their long-term investment horizon and their commitment to maintaining a strong balance sheet at ASA. We look forward to working with Lindsay Goldberg to build dynamic businesses in radiation therapy and dialysis services and to identify other sectors in which we can succeed."

Following the investment, Lindsay Goldberg will name three members of ASA's Board of Directors and will have a priority right to make additional investments in ASA.

About ASA

Ambulatory Services of America, head
'/>"/>

SOURCE Ambulatory Services of America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
2. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
3. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
4. Ambulatory Services of America, Inc. Announces Joint Venture with Southern Ocean County Radiation Oncology, LLC
5. Reproductive Science Center of New England Receives Ambulatory Health Care Accreditation
6. Ambulatory Services of America, Inc. Announces Joint Venture With Denton Cancer Center, LP
7. Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education
8. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
9. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
10. Tata Consultancy Services to Support Roches Global Capacity Building Initiative
11. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:eDiets.com(R) Announces Q3 2008 Results 2Health News:eDiets.com(R) Announces Q3 2008 Results 3Health News:eDiets.com(R) Announces Q3 2008 Results 4Health News:eDiets.com(R) Announces Q3 2008 Results 5Health News:eDiets.com(R) Announces Q3 2008 Results 6Health News:eDiets.com(R) Announces Q3 2008 Results 7Health News:Pelvic Inflammation Puts Girls at Risk for Repeat STIs 2Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 2Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 3Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 4Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 2Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 3Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 4Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 5Health News:Leading Scientists From Around the World Headed to Kansas for Symposium on Combating Deadly Infectious Diseases 2Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 2Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 3Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 4
Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Preventing toxic shock syndrome and other severe diseases 53247 1Got zinc 3F New zinc research suggests novel therapeutic targets 9433 1Got zinc 3F New zinc research suggests novel therapeutic targets 9433 2Recovery act funded research projects aid communities across the country 9428 1